Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 267 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Sclerosis (Scleroderma) Clear all
Completed No phase listed Observational

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

NCT02887495
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 15, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions
Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
51
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Psychological Treatments for Scleroderma

NCT00007267
View directory record Official record
Conditions
Pain, Depression, Scleroderma, Systemic Sclerosis
Interventions
Cognitive behavioral therapy, Disease/health education, Self-help cognitive behavioral intervention facilitated by a psychologist
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 15, 2026, 4:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
Orange, California • Gainesville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
rapcabtagene autoleucel, rituximab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Suspended Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

NCT06210945
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
10 mg/kg CM-101, Placebo
Drug
Lead sponsor
ChemomAb Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Scleroderma Treatment With Autologous Transplant (STAT) Study

NCT01413100
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Not applicable Interventional

RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach

NCT06999226
View directory record Official record
Conditions
Scleroderma
Interventions
RENEW-AI
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 15, 2026, 4:13 PM EDT
Terminated Early Phase 1 Interventional Results available

Molecular Effects of Topical Calcipotriene on Morphea

NCT02411643
View directory record Official record
Conditions
Morphea, Localized Scleroderma
Interventions
topical calcipotriene 0.005% ointment
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

NCT05029336
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Depletion of CD3/CD19 in an autologous stem cell transplant
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
8 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil in Systemic Sclerosis

NCT00433186
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin in the Treatment of Raynaud's

NCT01233999
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 15, 2026, 4:13 PM EDT
Terminated No phase listed Observational

Mindfulness Based Stress Reduction in Rheumatic Diseases

NCT03411057
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
Interventions
Mindfulness Based Stress Reduction (MBSR), Control
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 15, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978
View directory record Official record
Conditions
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions
FT819, Fludarabine, Cyclophosphamide, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
16
States / cities
Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

NCT00812188
View directory record Official record
Conditions
Symmetric Limited Morphea
Interventions
Medium Dose UVA-1, High Dose UVA-1
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 15, 2026, 4:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01474109
View directory record Official record
Conditions
Systemic Sclerosis, Ulcers
Interventions
macitentan 3mg, macitentan 10mg, placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 15, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT04915950
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 15, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Making it Work Program for Systemic Sclerosis

NCT06338722
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Making it Work Systemic Sclerosis
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 67 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 15, 2026, 4:13 PM EDT
Withdrawn Phase 1 Interventional

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

NCT06377228
View directory record Official record
Conditions
Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Interventions
TAK-007, Chemotherapy Agents
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Imatinib in Systemic Sclerosis

NCT00506831
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Imatinib mesylate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 15, 2026, 4:13 PM EDT
Completed No phase listed Observational

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

NCT01667042
View directory record Official record
Conditions
Scleroderma Lung
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 15, 2026, 4:13 PM EDT
Completed Phase 2Phase 3 Interventional

Lab Study of MQX-503 in Treatment of Raynaud's

NCT00253331
View directory record Official record
Conditions
Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
Interventions
topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 15, 2026, 4:13 PM EDT